次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

鎮痛薬(疼痛緩和薬)の世界市場2014-2024年

Pain Relieving Drugs Market Forecast 2014-2024
Future Prospects for Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年9月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文323ページになります。
商品コード:VGN280

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
当レポートでは、鎮痛薬(疼痛緩和薬)の世界市場は2014年に682億ドルに達すると推計しています。高齢化する人口、癌、関節炎、糖尿病などの疾患増加は鎮痛薬の売上増大要因となるでしょう。ドラッグデリバリーの改善や新製剤の登場も市場にとって重要です。地域的には特にブラジル、ロシア、インド、中国などのBRIC諸国で継続的な成長が見込まれます。新製品承認と乱用抵抗性を有する薬剤の開発は市場へインパクトを与えるイベントとなるでしょう。当レポートでは2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、研究開発動向、リーディング企業情報などを概略以下の構成でお届けいたします。

【レポート構成概要】
・鎮痛薬(疼痛緩和薬)の世界市場予測2014-2024年
・全323ページ、265個のデータ表、グラフ類で分析定量化
・成長率、市場シェア情報
・業界専門家オピニオンインタビュー:
• Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
• Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

・セグメント別市場予測2014-2024年
• 麻薬性鎮痛薬VGN280_Pain Relieving Drugs Market Forecast 2014-2024 Cover.jpgレポート表紙
• 神経因性疼痛緩和薬
• 関節炎治療
• 非麻薬性鎮痛薬
• 偏頭痛治療
• その他疼痛緩和薬

・主要28製品、製品別売上予測2014-2024年
(※以下ブランドを含む全28製品予測掲載、OTCおよび処方薬含む)
• Celebrex
• Voltaren
• Relpax
• Lyrica
• Cymbalta
• Aspirin
• Zomig
• Duragesic
• Oxycontin ER
• Panadol
• Lidoderm

・主要13ヶ国、国別市場予測2014-2024年
• 米国
• 日本
• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• ブラジル
• ロシア
• インド
• 中国
• トルコ
• 韓国
• その他地域Rest of the World

・研究開発(R&D)状況、開発パイプライン
• 麻薬性鎮痛薬
• 神経因性疼痛緩和薬
• 関節炎疼痛緩和薬
• 非麻薬性鎮痛薬
• 偏頭痛緩和薬

・市場動向分析
• 費用回収、当局規制、特許期限切れ、ジェネリックとの競合、OTCへのシフト
• コスト削減と効率化
• 抗てんかん薬、鎮痛薬、COX-2阻害剤、新しいオピオイド、カンナビノイドおよび局所麻酔薬
• 薬物耐性および依存の克服
• リウマチ関節への生物製剤の使用(例:モノクロナール抗体)
• 疾患修復性抗リウマチ薬Disease modifying anti-rheumatic drugs (DMARDs)
• 非ステロイド性抗炎症薬(NSAID)、コルチコステロイドおよびアルドースレダクターゼ阻害剤
• 疼痛経路と作用メカニズムの理解
• 安全性と患者コンプライアンス
• 製品効能を支持する臨床的エビデンス

・主要企業
Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb、その他製薬企業に言及

Visiongain is a trading partner with the US Federal Government.
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies

Table of Contents

1. Report Overview

1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Pain and Pain Management

2.1 Pain: A Sensory And Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways And The Origin Of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification Of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects Of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry Of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management – A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use Of Opioids In Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition

3. World Pain Relieving Drugs Market 2014-2024

3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2013
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2014-2024

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
4.1.2 Changing Market Shares By Leading Drugs 2014-2024
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
4.2.3 Opana ER: Sales Forecast 2014-2024
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
4.3.2 Duragesic: Sales Forecast 2014-2024
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2014-2024
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2014-2024
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
5.1.2 Changing Market Shares By Leading Drugs 2014-2024
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2008-2013
5.3.2 Panadol: Sales Forecast 2014-2024
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
5.4.2 Advil: Sales Forecast 2014-2024
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2014-2024
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024

6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
6.1.5 Changing Market Shares By Leading Drugs 2014-2024
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma – Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
6.2.4 Lidoderm: Sales Forecast 2014-2024
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
6.3.2 Lyrica: Sales Forecast 2014-2024
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
6.4.2 Cymbalta: Sales Forecast 2014-2024
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
6.5.2 Neurontin: Sales Forecast 2014-2024
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
6.6.2 Nucynta: Sales Forecast 2014-2024
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024

7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024

7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used In the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
7.1.6 Changing Market Shares By Leading Drugs 2014-2024
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2009-2013
7.2.2 Relpax: Sales Forecast 2014-2024
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
7.3.2 Maxalt: Sales Forecast 2014-2024
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2009-2013
7.5.3 Zomig: Sales Forecast 2014-2024
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2009-2013
7.6.2 Botox: Sales Forecast 2014-2024
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2008-2013
7.7.4 Treximet: Sales Forecast 2014-2024
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2011-2013
7.8.2 Axert: Sales Forecast 2014-2024
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
7.10 Anti-Migraine Pain Relieving Drugs Market – Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024

8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In The Treatment Of Arthritis
8.1.2.1 Analgesics As Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment Of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2011-2013
8.2.2 Humira: Sales Forecast 2014-2024
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
8.3.4 Enbrel: Sales Forecast 2014-2024
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2008-2013
8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
8.4.3 Remicade: Sales Forecast 2014-2024
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
8.5.2 Voltaren: Sales Forecast 2014-2024
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
8.6.3 Rituxan: Sales Forecast 2014-2024
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
8.7.3 Celebrex: Sales Forecast 2014-2024
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
8.8.2 Arcoxia: Sales Forecast 2014-2024
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
8.10 Anti-Arthritic Pain Relieving Drug Market – Future Prospects

9. Leading National Markets for Pain Relieving Drugs 2014-2024

9.1 The Pain Relieving Drug Market By Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
9.2 Leading National Markets: Forecast, 2014-2024
9.2.1 Changing Market Shares By Region, 2014-2024
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 South Korea
9.9 Brazil
9.10 India
9.11 Russia
9.12 Turkey
9.13 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2014-2024

10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx - COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance To Drug Development
10.9 Monoclonal Antibodies (MAbs) – Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities For Growth
10.11 The Potential Use Of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024

11.1 Market Factors Influencing The Pain Relieving Drugs Market
11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates In The R&D Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education In Pain Management Is A Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population – Growth Driver For Pain Relieving Drugs
11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead To Generic Competition
11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
11.3.4 Political Factors Affecting The Pain Relieving Drugs Market

12. Expert Opinions

12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
12.1.1 Pain Relieving Drugs: Current Trends In The Market
12.1.2 Nektar’s NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
12.1.4 Nektar’s Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
12.1.5 Future Expansion Plans
12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
12.2.1 The Quest For Alternative Pain Relief Therapies
12.2.2 The Future Potential Of Combination Therapies In Pain Relief
12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
12.2.4 On The Market Potential Of Spinifex’s EMA401 Product
12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics

13. Conclusions

13.1 Market Overview
13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
13.3 Major Growth Drivers For Pain Relieving Drugs
13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
13.8 Emerging Markets Set To Drive Steer Market Forward
13.9 What Does The Future Hold For Pain Relieving Drugs?

List of Tables

Table 1.1 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 1.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 2.1 Comparison of Acute and Chronic Pain
Table 2.2 Therapeutic Classes In Pain Management
Table 3.1 The Global Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
Table 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
Table 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
Table 3.4 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Table 3.5 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
Table 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 4.3 The Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 4.5 Opana ER: Historical Sales ($m, AGR%), 2011-2013
Table 4.6 Opana ER: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.7 Duragesic: Historical Sales ($m, AGR%), 2011-2013
Table 4.8 Duragesic: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.9 Oxycontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.10 Ultram: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.11 Zaldiar/Ixprim: Historical Sales ($m, mEuros, AGR%), 2010-2013
Table 4.12 Zaldiar/Ixprim: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.13 Other Narcotic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 5.3 The Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 5.5 Aspirin and Aspirin Cardio: Historical Sales ($m, mEuros, AGR%), 2010-2013
Table 5.6 Aspirin (Bayer): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.7 Panadol Formulations, 2014
Table 5.8 Panadol (GSK): Historical Sales ($m, £m, AGR%), 2008-2013
Table 5.9 Panadol (GSK): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.10 Selected Advil Products and Product Details, 2014
Table 5.11 Advil: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.12 Selected Tylenol Products and Product Details, 2014
Table 5.13 Tylenol: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.14 Other Non-Narcotic Pain Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.1 Key Drug Indications for Neuropathic Pain, 2014
Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2014
Table 6.3 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 6.4 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 6.5 The Neuropathic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 6.6 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 6.7 Lidoderm: Historical Sales ($m, AGR%), 2009-2013
Table 6.8 Lidoderm: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.9 Lyrica: Historical Sales ($m, AGR%), 2009-2013
Table 6.10 Lyrica: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.11 Cymbalta: Historical Sales ($m, AGR%), 2008-2013
Table 6.12 Cymbalta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.13 Neurontin: Historical Sales ($m, AGR%), 2009-2013
Table 6.14 Neurontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.15 Nucynta: Historical Sales ($m, AGR%), 2010-2013
Table 6.16 Nucynta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.17 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 7.3 The Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 7.5 Relpax: Historical Sales ($m, AGR%), 2009-2013
Table 7.6 Relpax: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.7 Maxalt: Historical Sales ($m, AGR%), 2008-2013
Table 7.8 Maxalt: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.9 Imitrex/Imigran: Historical Sales ($m, £m, AGR%), 2008-2013
Table 7.10 Imitrex/Imigran: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.11 Zomig: Historical Sales ($m, AGR%), 2009-2013
Table 7.12 Zomig: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.13 Botox (Allergan): Historical Sales ($m, AGR%), 2009-2013
Table 7.14 Botox: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.15 Treximet: Historical Sales ($m, AGR%), 2008-2013
Table 7.16 Treximet: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.17 Axert: Historical Sales ($m, AGR%), 2011-2013
Table 7.18 Axert: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.19 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.1 Selected Examples of Anti-Arthritic Pain Relieving Drugs, 2014
Table 8.2 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 8.3 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 8.6 Humira: Historical Sales ($m, AGR%), 2010-2013
Table 8.7 Humira: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2013
Table 8.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.10 Remicade: Historical Sales ($m, bn Yen, AGR%) by Company, 2008-2013
Table 8.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.12 Voltaren: Historical Sales ($m, AGR%), 2008-2013
Table 8.13 Voltaren: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.14 Rituxan: Historical Sales ($m, bn Yen, AGR%), 2008-2013
Table 8.15 Rituxan: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.16 Celebrex: Historical Sales ($m, AGR%), 2008-2013
Table 8.17 Celebrex: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.18 Arcoxia: Historical Sales ($m, AGR%), 2008-2013
Table 8.19 Arcoxia: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.1 The Global Pain Relieving Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
Table 9.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 9.3 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
Table 9.4 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2013, 2018, 2024
Table 9.5 US Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.6 US Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.7 The EU5 Pain Relieving Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 9.8 The EU5 Pain Relieving Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
Table 9.9 EU5 Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.10 The EU5 Pain Relieving Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
Table 9.11 The German Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.12 The German Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.13 The UK Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.14 The UK Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.15 French Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.16 French Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.17 Italian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.18 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.19 Spanish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.21 Japanese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.22 Japanese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.23 Chinese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.24 Chinese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.25 South Korean Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.26 South Korean Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.27 Brazilian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.28 Brazilian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.29 Indian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.30 Indian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.31 Russian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.32 Russian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.33 Turkish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.34 Turkish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.35 Rest of the World Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.36 Rest of the World Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 10.1 R&D Pipeline for Narcotic Pain Relieving Drugs, 2014
Table 10.2 R&D Pipeline for Non-Narcotic Pain Relieving Drugs, 2014
Table 10.3 R&D Pipeline for Neuropathic Pain Relieving Drugs, 2014
Table 10.4 R&D Pipeline for Anti-Migraine Pain Relieving Drugs, 2014
Table 10.5 R&D Pipeline for Anti-Arthritis Pain Relieving Drugs, 2014
Table 11.1 Pain Relieving Drugs: Market Drivers and Restraints 2014-2024
Table 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2014-2024
Table 11.3 Global Population Forecast: Total Population (bn, CAGR %) and Over-65 Population (bn, CAGR%), 2012, 2015, 2018, 2023
Table 11.4 STEP Analysis of the Pain Relieving Drugs Market, 2014-2024
Table 13.1 Pain Relieving Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
Table 13.2 Pain Relieving Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024
Table 13.3 Global Pain Relieving Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024

List of Figures

Figure 1.1 Global Population Forecast: Total Population (bn) and Over-65 Population (bn), 2012, 2015, 2018, and 2023
Figure 1.2 Global Pain Relieving Drugs Market: Submarkets, 2014
Figure 2.1 Categories of Pain
Figure 3.1 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013
Figure 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2018
Figure 3.4 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2018-2024
Figure 3.5 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2024
Figure 3.6 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2013
Figure 3.8 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2018
Figure 3.9 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2024
Figure 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 4.3 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 4.5 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
Figure 4.6 Opana ER: Historical Sales ($m, AGR%), 2011-2013
Figure 4.7 Opana ER: Sales Forecast ($m, AGR%), 2013-2024
Figure 4.8 Duragesic: Historical Sales ($m, AGR%), 2011-2013
Figure 4.9 Duragesic: Sales Forecast ($m, AGR%), 2013-2024
Figure 4.10 Oxycontin: Sales Forecast ($m, AGR%), 2013-2024
Figure 4.11 Ultram: Sales Forecast ($m, AGR%), 2013-2024
Figure 4.12 Zaldiar/Ixprim: Historical Sales (mEuros, AGR%), 2010-2013
Figure 4.13 Zaldiar/Ixprim: Sales Forecast ($m, AGR%), 2013-2024
Figure 4.14 Other Narcotic Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
Figure 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 5.3 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 5.5 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
Figure 5.6 Aspirin and Aspirin Cardio: Historical Sales (mEuros, AGR%), 2010-2013
Figure 5.7 Aspirin (Bayer): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.8 Panadol (GSK): Historical Sales (£m, AGR%), 2008-2013
Figure 5.9 Panadol (GSK): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.10 Advil: Sales Forecast ($m, AGR%), 2013-2024
Figure 5.11 Tylenol: Sales Forecast ($m, AGR%), 2013-2024
Figure 5.12 Other Non-Narcotic Pain Drugs: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.1 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 6.2 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 6.3 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 6.4 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 6.5 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
Figure 6.6 Lidoderm: Historical Sales ($m, AGR%), 2009-2013
Figure 6.7 Lidoderm: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.8 Lyrica: Historical Sales ($m, AGR%), 2009-2013
Figure 6.9 Lyrica: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.10 Cymbalta: Historical Sales ($m, AGR%), 2008-2013
Figure 6.11 Cymbalta: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.12 Neurontin: Historical Sales ($m, AGR%), 2009-2013
Figure 6.13 Neurontin: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.14 Nucynta: Historical Sales ($m, AGR%), 2010-2013
Figure 6.15 Nucynta: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.16 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.3 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 7.5The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2024
Figure 7.6 Relpax: Historical Sales ($m, AGR%), 2009-2013
Figure 7.7 Relpax: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.8 Maxalt: Historical Sales ($m, AGR%), 2008-2013
Figure 7.9 Maxalt: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.10 Imitrex/Imigran: Historical Sales (£m, AGR%), 2008-2013
Figure 7.11 Imitrex/Imigran: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.12 Zomig: Historical Sales ($m, AGR%), 2009-2013
Figure 7.13 Zomig: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.14 Botox (Allergan): Historical Sales ($m, AGR%), 2009-2013
Figure 7.15 Botox: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.16 Treximet: Historical Sales ($m, AGR%), 2008-2013
Figure 7.17 Treximet: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.18 Axert: Historical Sales ($m, AGR%), 2011-2013
Figure 7.19 Axert: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.20 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.1 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 8.2 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 8.3 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by leading Drugs, 2024
Figure 8.6 Humira: Historical Sales ($m), 2008-2013
Figure 8.7 Humira: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.8 Enbrel: Historical Sales ($m) by Company, 2008-2013
Figure 8.9 Enbrel: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.10 Remicade: Historical Sales ($m) by Company, 2008-2013
Figure 8.11 Remicade: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.12 Voltaren: Historical Sales ($m), 2008-2013
Figure 8.13 Voltaren: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.14 Rituxan: Historical Sales ($m), 2008-2013
Figure 8.15 Rituxan: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.16 Celebrex: Historical Sales ($m), 2008-2013
Figure 8.17 Celebrex: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.18 Arcoxia: Historical Sales ($m), 2008-2013
Figure 8.19 Arcoxia: Sales Forecast ($m, AGR%), 2013-2024
Figure 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($m, AGR%), 2013-2024
Figure 9.1 The Global Pain Relieving Drugs Market: Market Size ($m) by Region, 2013
Figure 9.2 US, EU5, Japan, and South Korea Pain Relieving Drugs Market: Market Forecast ($m), 2013-2024
Figure 9.3 Brazil, Russia, India, China, and Turkey Pain Relieving Drugs Markets: Market Forecasts ($m), 2013-2024
Figure 9.4 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2018
Figure 9.5 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2018-2024
Figure 9.6 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2024
Figure 9.7 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2013
Figure 9.8 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2018
Figure 9.9 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2024
Figure 9.10 US Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.11 The EU5 Pain Relieving Drugs Market: Revenues ($m) by Country, 2013
Figure 9.12 Germany, France, UK, Italy, and Spain Pain Relieving Drugs Market: Market Forecast ($m), 2013-2024
Figure 9.13 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2013
Figure 9.14 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2018
Figure 9.15 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2024
Figure 9.16 German Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.17 The UK Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.18 French Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.19 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.21 Japanese Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.22 Chinese Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.23 South Korean Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.24 Brazilian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.25 Indian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.26 Russian Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.27 Turkish Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.28 Rest of the World Pain Relieving Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 11.1 Global Population Forecast: Total Population (bn) and Over-65 Population (bn), 2012, 2015, 2018, 2023
Figure 13.1 Pain Relieving Drugs: Market Forecast ($m), 2013, 2018, 2021, 2024
Figure 13.2 Pain Relieving Drugs: Market Forecast ($m) by Sector, 2013-2024



掲載企業リスト

Companies Listed

AB Science
Abbott Laboratories
AcelRx Pharmaceuticals
Actavis (Watson)
Acura
Afferent Pharmaceuticals
Alkem Laboratories
Allergan
Almirall
AlphaPharm
Alza Corporation
Amgen
Aoxing Pharmaceutical Company Inc
Apotex Corp
Arcion Therapeutics
Ascend Laboratories
AstraZeneca
Avanir
Bayer
Biodelivery Sciences
Biogen Idec
Boston Millennia Partners
Brigham Young University (BYU)
Bristol-Myers Squibb
Care Capital
Celltrion
CeNeS
Centocor Ortho Biotech (J&J)
Chugai
Cilag GmbH International (J&J)
CK Life Sciences
Collegium
CoLucid Pharmaceuticals
Convergence Pharmaceuticals
Depomed
Domain Associates
Dr Reddy’s Laboratories
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
Eurocept BV
Exemplar Pharma
Forest Laboratories
Frazer Healthcare Ventures
Galen
Genentech (Roche)
Genmab
Gilead Sciences
GlaxoSmithKline
Grunenthal Group
Horizon Pharma
Hospira
Human Genome Sciences
Immune Pharmaceuticals
Impax Laboratories
Insys Therapeutics
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johnson&Johnson
Kaiser Foundation Health Plan Inc
King Pharmaceuticals (Pfizer)
Kyorin
Longitude Capital
Lundbeck
Lupin Pharmaceuticals
McNeil Consumer Healthcare (J&J)
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Monsanto
Mylan
Nektar Therapeutics
NeurAxon Inc
NeurogesX
Neurotune
Newron Pharmaceuticals
NicOx
Novartis
NuPathe (Teva)
Nuvo Research
Omeros
Ono Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Pappas Ventures
Par Pharmaceutical
Pearl Street Venture Funds
Penwest Pharmaceuticals
Pernix Therapeutics Holding Inc
Pfizer
Pharmacia
PLx Pharma
Pozen Pharmaceuticals
Proteus SA
Purdue Pharma
QRx Pharma
Ranbaxy
Ratiopharm
Rinat (Pfizer)
Roche
Roxane Laboratories
Sandoz (Novartis)
Sanofi
Schering-Plough (Merck & Co)
Shionogi & Co Ltd
Shire
Skye Pharma
Skyline Ventures
Spinifex Pharmaceuticals
Stada Arzneimittel AG
Syntaxin
Takeda
Teikoku
Teva
Triathlon Medical Ventures
UCB
US WorldMeds
Valeant
Watson Pharmaceuticals
WEX Pharmaceuticals
Zars Pharmaceuticals (Nuvo Research)
Zogenix

Organisations Mentioned In The Report

Boston Children Hospital [US]
Center for Medicare and Medicaid Services
Committee for Medicinal Products for Human Use (CHMP)
European Commission
Federal Drug Control Service [Russia]
International Association for the Study of Pain (IASP)
National Institute for Health and Care Excellence (NICE)
The American Pain Society
The Arthritis Foundation
The International Diabetes Federation
The National Institute for Population and Social Security Research (IPSS) [Japan]
US Census Bureau
US Food and Drug Administration (FDA)
US Justice Department
US Patent and Trademark Office
US Society for Neuroscience
World Health Organisation (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

疼痛管理装置(ペインマネジメント)の世界市場2014-2024年

疼痛管理(ペインマネジメント)装置の世界市場は2014年に33億3600万ドルに達し、2024年にかけて堅調な成長を遂げることが見込まれます。鎮痛薬の耐性と依存の問題を改善する技術は特に成功の見込みが高いといえます。また神経刺激関連デバイスの使用増加傾向は、市場全体の促進要因となるでしょう。

レポートページへLinkIcon

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。